Zentalis Pharmaceuticals (ZNTL)
(Delayed Data from NSDQ)
$1.52 USD
+0.03 (2.01%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $1.54 +0.02 (1.32%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth A Momentum B VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
ZNTL 1.52 +0.03(2.01%)
Will ZNTL be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ZNTL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ZNTL
Zentalis Pharmaceuticals (ZNTL) Loses -46.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Zentalis Pharmaceuticals (ZNTL) Upgraded to Strong Buy: What Does It Mean for the Stock?
ZNTL: What are Zacks experts saying now?
Zacks Private Portfolio Services
New Strong Buy Stocks for January 9th
Other News for ZNTL
Is ZNTL ready to move higher? Pocket Pivot shows up after climbing 2.01%
Stochastic Buy Signal appears for ZNTL after 4.93% move
The technical outlook for ZNTL is unchanged after sideways trading on September 17
H.C. Wainwright Remains a Buy on Zentalis Pharmaceuticals (ZNTL)
New Downtrend appears for ZNTL after 2.07% move